Improved Clinical Flow Cytometry Accuracy with ClearLLab LS Lymphoid Screen Reagent

Beckman Coulter Life Sciences further has demonstrated its expertise in clinical flow cytometry with the launch of ClearLLab LS Lymphoid Screen Reagent, Europe’s first CE-marked 10-colour, 12 antibody reagent combination for leukemia and lymphoma analysis.

The ClearLLab LS Lymphoid Screen delivers greater confidence in results with a faster turnaround time (TAT). It eliminates 14 manual workflow steps, while streamlining five others; and is available through a dry unitized, ready to use formulation. ClearLLab has been specifically designed for the fast and accurate identification of hematolymphoid cell populations on the company’s Navios flow cytometer.

Mario Koksch, vice president and general manager of Beckman Coulter’s Cytometry Business Unit said: “Beckman Coulter provides lab scientists with the tools they need to standardize and streamline workflow when using high content flow cytometry in clinical decision-making. By eliminating 14 workflow steps, we empower them to achieve much faster and more consistent turnaround times.”

Flow cytometry offers significant advantages over other cell-based techniques, such as precision, speed, the preservation of cell viability and cellular functions, and simultaneous measurements of multiple cellular parameters. As Dr Kosch explained: “If survival rates are to be improved, we need to be able to diagnose life-threatening hematolymphoid diseases as quickly as possible. With ClearLLab LS Lymphoid Screen, the lab now has the means to speed up the delivery of patient results to clinicians, while having added confidence in their accuracy.”

The ClearLLab LS Lymphoid Screen is the first of an advanced range of Beckman Coulter clinical flow cytometry products which will cater to different global workflow requirements over the next five years. It is compatible with the World Health Organization (WHO) 2008-revised classification of myeloid neoplasms and acute leukemia. WHO, in collaboration with the European Association for Hematopathology and the Society for Hematopathology, made important changes to the classification of these diseases, including new criteria for the recognition of some previously described neoplasms as well as clarification and refinement of the defining criteria for others.